Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20223056 | 0.85 | KDM4E (0.41) | KDM4ELMNAHSP90AB1HSP90AA1KMT2A | |
| SCHEMBL20223478 | 0.77 | TTR (0.43) | KDM4EKMT2ARAB9AHCAR2MAPT | |
| SCHEMBL30036780 | 0.77 | TTR (0.43) | KDM4EKMT2ARAB9AHCAR2MAPT | |
| SCHEMBL27403418 | 0.74 | HSP90AB1 (0.43) | KDM4ELMNAHSP90AB1HSP90AA1KMT2A | |
| SCHEMBL3187493 | 0.72 | GRM4 (0.66) | KDM4EHSP90AB1HSP90AA1KMT2AMEN1 | |
| SCHEMBL3187486 | 0.72 | GRM4 (0.66) | KDM4EHSP90AB1HSP90AA1KMT2AMEN1 | |
| SCHEMBL21200646 | 0.72 | HCAR2 (0.48) | KDM4ELMNAKMT2ANPSR1MEN1 | |
| SCHEMBL21200743 | 0.72 | HCAR2 (0.48) | KDM4ELMNAKMT2ANPSR1MEN1 | |
| SCHEMBL7420123 | 0.71 | HSP90AB1 (0.42) | KDM4ELMNAHSP90AB1HSP90AA1KMT2A | |
| SCHEMBL10619597 | 0.71 | CYP2D6 (0.40) | KDM4ELMNAHSP90AB1HSP90AA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110177780-B | Pyrimidine compounds containing acidic groups | 阿普罗斯治疗公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-3548478-B1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | APROS THERAPEUTICS INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210000826-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS AS TLR7 MODULATORS | Apros Therapeutics, Inc. | 2021-01-07 | — | — | US | disclosed |
| US-10786502-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190314372-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. | 2019-10-17 | — | — | US | disclosed |
| EP-3548478-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10287253-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2019-05-14 | — | — | US | disclosed |
| WO-2018106606-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20180155298-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000826-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS AS TLR7 MODULATORS | TLR7, TLR9, STING1 | KDM4E 2413/4885LMNA 4121/4885HSP90AB1 1814/4885 |
| US-20180155298-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | MAVS, TLR7, STING1 | KDM4E 3029/4885LMNA 4274/4885HSP90AB1 1708/4885 |
| US-20190314372-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | MAVS, TLR7, STING1 | KDM4E 3029/4885LMNA 4274/4885HSP90AB1 1708/4885 |
| US-10287253-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | TLR7, TLR9, MAVS | KDM4E 2050/4885LMNA 4400/4885HSP90AB1 1257/4885 |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | TLR7, TLR9, MAVS | KDM4E 2050/4885LMNA 4400/4885HSP90AB1 1257/4885 |
| US-10786502-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | TLR7, TLR9, MAVS | KDM4E 2050/4885LMNA 4400/4885HSP90AB1 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.